Clinical trial of 2 bromo α ergocryptine (NSC 169774) in human prostatic cancer

Abstract

An EORTC type I clinical trial of 2 bromo α ergocryptine was performed in patients with prostatic carcinoma in clinical stages III and IV. Evaluating rules of response to the therapy were based on objective criteria. The maximum period of followup was 16 wk. No objective remissions were observed in 24 patients, and in 13 of these patients, evidence of progression of the disease was apparent during the first 8 wk of drug administration.SCOPUS: ar.jinfo:eu-repo/semantics/publishe